PDL BioPharma Inc (PDLI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PDL BioPharma Inc (PDLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9915
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to late-stage public and private healthcare companies. PDL provides companies, academic institutions, and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc (PDLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Licensing Agreements 20
Lee’s Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Equity Offering 22
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
Debt Offering 23
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc – Key Competitors 27
PDL BioPharma Inc – Key Employees 28
PDL BioPharma Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 06, 2018: PDL BioPharma reports third quarter 2018 financial results 30
Aug 08, 2018: PDL BioPharma reports second quarter 2018 financial results 32
May 09, 2018: PDL BioPharma Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results 35
Nov 02, 2017: PDL BioPharma Announces Third Quarter 2017 Financial Results 37
Aug 03, 2017: PDL BioPharma Announces Second Quarter 2017 Financial Results 40
May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 42
Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 44
Corporate Communications 46
Jun 22, 2018: Elizabeth O’Farrell Named to PDL BioPharma’s Board of Directors 46
Jun 11, 2018: PDL BioPharma Appoints Shlomo Yanai As Board Director 47
Sep 11, 2017: PDL BioPharma Appoints Dominique Monnet as President 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 12
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 13
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 15
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 17
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 18
Lee's Pharma Enters into Licensing Agreement with Noden Pharma 20
PDL BioPharma Enters into Royalty Agreement with AxoGen 21
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 22
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 23
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 24
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 26
PDL BioPharma Inc, Key Competitors 27
PDL BioPharma Inc, Key Employees 28
PDL BioPharma Inc, Subsidiaries 29

List of Figures
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PDL BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[PDL BioPharma Inc (PDLI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Terumo Corp (4543):企業の製品パイプライン分析2018
    Summary Terumo Corp (Terumo) is a medical technology company, which manufactures and sells a wide range of medical care products including hospital and medical products, and equipment. Its major product categories include vascular interventional products, cardiovascular surgical systems, artificial …
  • OFG Bancorp (OFG):企業の財務・戦略的SWOT分析
    Summary OFG Bancorp (OFG) operates as a financial service provider that offers banking, treasury, and financial products and services. The company’s consumer banking and lending products comprise residential mortgages, consumer finance, auto loans, and credit cards. Its commercial banking products a …
  • Latecoere S.A.:企業の戦略・SWOT・財務情報
    Latecoere S.A. - Strategy, SWOT and Corporate Finance Report Summary Latecoere S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Ambu AS (AMBU B):企業の財務・戦略的SWOT分析
    Ambu AS (AMBU B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Biofortuna Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Biofortuna Ltd (Biofortuna) is a provider of contract services and molecular diagnostic products. The company distributes CE-marked and freeze-dried PCR diagnostic kits. It has freeze dried molecular diagnostic products targeted at the transplantation, disease identification and pharmacogene …
  • Pellegrini S.p.A.:企業の戦略・SWOT・財務分析
    Pellegrini S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pellegrini S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Wells Fargo Private Bank:企業の戦略・SWOT・財務情報
    Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report Summary Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Provectus Biopharmaceuticals Inc (PVCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Provectus Biopharmaceuticals Inc (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications. The company provides pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], …
  • Ovensa Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ovensa Inc (Ovensa) is a preclinical stage company that develops nanotherapeutics. The company uses its proprietary Triozan Nanomedicine delivery platform that has mucosal and brain-barrier crossing properties used in treatment of oncology and neurodegenerative diseases. Its Triozan helps in …
  • Outlook Therapeutics Inc (ONSIU):企業の財務・戦略的SWOT分析
    Summary Outlook Therapeutics Inc (Outlook Therapeutics), formerly Oncobiologics Inc, is a biopharmaceutical company that develops, manufactures and commercializes biosimilar products in the areas of ophthalmology. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formul …
  • University of Wollongong:企業の戦略的SWOT分析
    University of Wollongong - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Allscripts Healthcare Solutions Inc (MDRX):企業の財務・戦略的SWOT分析
    Allscripts Healthcare Solutions Inc (MDRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Power Grid Corporation of India Limited:企業の戦略・SWOT・財務情報
    Power Grid Corporation of India Limited - Strategy, SWOT and Corporate Finance Report Summary Power Grid Corporation of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • The Empire District Electric Company:発電所・企業SWOT分析
    The Empire District Electric Company - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Hanger, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Hanger, Inc. (Hanger) formerly Hanger Orthopedic Group, Inc., is a health care and medical device company. The company along with its subsidiaries offers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions. Hanger is one of the largest owner …
  • Vonage Holdings Corp:企業の戦略・SWOT・財務分析
    Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Prinzhorn Holding GmbH:企業の戦略・SWOT・財務情報
    Prinzhorn Holding GmbH - Strategy, SWOT and Corporate Finance Report Summary Prinzhorn Holding GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CPR Pharma Services Pty Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary CPR Pharma Services Pty Ltd (CPR) is a contract research organization that offers drug development and clinical trial services. The organization's services include clinical project management and monitoring, data management, statistical and pharmacokinetic services, and bioanalytical service …
  • MedSynergies Inc:医療機器:M&Aディール及び事業提携情報
    Summary MedSynergies Inc (MedSynergies), a subsidiary of Optum Inc, is a healthcare service provider that offers services in business aspects of medicine. The company offers revenue cycle management, consulting services, practice management, business process analysis and software integration solutio …
  • Reply S.p.A. (REY):企業の財務・戦略的SWOT分析
    Reply S.p.A. (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆